Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 4/20 | 0.31 |
| ▸ | NPY1R | P25929 | 3/20 | 0.31 |
| ▸ | NPY2R | P49146 | 3/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118988 | 1.00 | ALOX15 (0.41) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| Arginine SCHEMBL1790 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| Arginine SCHEMBL6374054 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| SCHEMBL11229239 | 0.82 | GPR84 (0.42) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| Arginine SCHEMBL7928810 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| Arginine SCHEMBL288132 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| Arginine SCHEMBL1791 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| SCHEMBL3351368 | 0.82 | GPR84 (0.42) | ALOX15MEN1KMT2ACYP1A2SMN1; SMN2 | |
| Arginine SCHEMBL2411547 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC | |
| Arginine SCHEMBL31663499 | 0.82 | OTC (0.56) | ALOX15MEN1KMT2ACYP1A2OTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002334-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION | 2024-01-04 | — | — | US | claimed |
| WO-2023177877-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION (US) | 2023-09-21 | — | — | WO | claimed |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | claimed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | claimed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | claimed |
| US-20240002334-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION | 2024-01-04 | — | — | US | disclosed |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-3884934-B1 | PHARMACEUTICAL COMPOSITION COMPRISING: 2-(((1R,4R)-4-(((4-CHLOROPHENYL)(PHENYL)CARBAMOYLOXY)METHYL)CYCLOHEXYL)METHOXY)ACETIC ACID | ARENA PHARM INC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023177877-A1 | RALINEPAG PRODRUGS AND USES THEREOF | UNITED THERAPEUTICS CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-110003123-B | Modulators of the PGI2 receptor for the treatment of prostacyclin (PGI 2) receptor related disorders | 艾尼纳制药公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2280696-B9 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| EP-2857015-A1 | Modulators of the prostacyclin (PG12) receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8895776-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2280696-B1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053958-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | ALOX15 92/4885MEN1 3308/4885KMT2A 4434/4885 |
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | ALOX15 126/4885MEN1 3214/4885KMT2A 2641/4885 |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | ALOX15 90/4885MEN1 3319/4885KMT2A 4432/4885 |
| US-20230121825-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PLOD3 | ALOX15 63/4885MEN1 3123/4885KMT2A 4525/4885 |
| US-20150126527-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | ALOX15 90/4885MEN1 3319/4885KMT2A 4432/4885 |
| US-20240002334-A1 | RALINEPAG PRODRUGS AND USES THEREOF | PTGIR, PTGIS, PTGER1 | ALOX15 400/4885MEN1 1306/4885KMT2A 2851/4885 |
| US-20230404954-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | ALOX15 92/4885MEN1 3308/4885KMT2A 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.